CXCL12 and mature T-cell and NK-cell non-Hodgkin lymphoma: Tipifarnib, a potent and selective inhibitor of farnesyltransferase, has been shown to modulate CXCL12 signaling pathway and has demonstrated promising preliminary results in patients with R/R AITL and CXCL12+ PTCL with ORR of 45% and a 73% clinical benefit rate [83] in a phase II trial in patients with R/R PTCL (NCT02464228).